CA
IBIO icon

Clearstead Advisors’s iBio IBIO Stock Holding History

Clearstead Advisors’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2
Closed -$13 – 1395
2022
Q4 		$13 Buy
+2
New +$68 ﹤0.01% 1303
2022
Q3 		– Hold
0
– – – 1299
2022
Q2 		– Hold
0
– – – 1356
2022
Q1 		– Hold
0
– – – 1416
2021
Q4 		– Hold
0
– – – 1351
2021
Q3 		– Hold
0
– – – 1333
2021
Q2 		– Hold
0
– – – 1281
2021
Q1 		– Hold
0
– – – 1146

Other funds holding IBIO

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Clearstead Advisors's IBIO Position: Q1 2023 in Review

Clearstead Advisors sold out of iBio (IBIO) in Q1 2023, closing a stake of 2 shares — an estimated $13 sold.

Clearstead Advisors first reported a position in IBIO in Q4 2022 and held it in 1 quarter. The position peaked at $13 in Q4 2022. 29 funds tracked by Wall St. Rank hold IBIO as of Q1 2023.

  • Clearstead Advisors reported no remaining iBio position as of Q1 2023 after selling out during the quarter.
  • Clearstead Advisors sold 2 iBio shares in Q1 2023, an estimated $13.
  • Clearstead Advisors first reported a position in iBio in Q4 2022 and held it in 1 quarter.
  • Clearstead Advisors's iBio position peaked at $13 in Q4 2022.
  • 29 funds tracked by Wall St. Rank held iBio as of Q1 2023.

Based on Clearstead Advisors's 13F filing for Q1 2023, filed 9 May 2023.